Evaluating the Efficacy and Safety of Orelabrutinib-Based Regimens in Diffuse Large B-Cell Lymphoma: A Retrospective Analysis
Abstract: Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous malignancy associated with significant morbidity and mortality. Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown promise as a therapeutic agent…